博舒替尼治疗耐药和不耐受的儿童慢性期慢性髓性白血病:ITCC054/COG AAML1921研究I期结果
这项国际开放标签I期试验采用6+4设计,在1-18岁耐药/不耐受的费城染色体阳性慢性髓性白血病儿童中测试博舒替尼300、350、400 mg/m2每日一次随餐给药的推荐II期剂量。30例入组、27例可评估剂量限制性毒性,最常见不良事件为腹泻(93%;≥3级11%)。结论认为博舒替尼安全有效,耐药/不耐受患者推荐II期剂量为400 mg/m2每日一次(最大600 mg/d)随餐,初诊患者为300 mg/m2每日一次(最大500 mg/d)随餐。
要点
- 耐药/不耐受儿童慢性期慢性髓性白血病博舒替尼推荐II期剂量为400 mg/m2每日一次(最大600 mg/d)随餐。
- 初诊患者推荐II期剂量为300 mg/m2每日一次(最大500 mg/d)随餐,基于耐药/不耐受患者数据选择。
- 最常见不良事件为腹泻(93%),≥3级腹泻占11%;7例因不耐受停药、8例因反应不足停药。
核心结论
- 博舒替尼安全有效,耐药/不耐受患者推荐II期剂量为400 mg/m2每日一次(最大600 mg/d)随餐,初诊患者为300 mg/m2每日一次(最大500 mg/d)随餐,达到成人经验对应的目标暴露。
研究设计与样本
- 国际开放标签I期试验(ClinicalTrials.gov标识:NCT04258943),入组1-18岁耐药/不耐受(按欧洲白血病网2013标准)费城染色体阳性慢性髓性白血病儿童,采用6+4设计测试300、350、400 mg/m2每日一次随餐给药。
- 推荐II期剂量定义为第一周期内0/6或1/10剂量限制性毒性且达到相应适应症成人目标AUC水平的剂量;初诊患者仅入组II期,其推荐II期剂量基于耐药/不耐受患者数据选择。
- 30例入组,27例可评估剂量限制性毒性:300 mg/m2组6例、350 mg/m2组11例(1例剂量限制性毒性)、400 mg/m2组10例(1例剂量限制性毒性)。
主要发现
- 300、350、400 mg/m2组平均AUC分别为2.20 μg h/mL、2.52 μg h/mL、2.66 μg h/mL。
- 最常见不良事件为腹泻(93%;≥3级11%)。
- 7例因不耐受停药,8例因反应不足停药。
- 博舒替尼的完全细胞遗传学反应和主要分子学反应与其他已发表的儿童第二代酪氨酸激酶抑制剂I/II期试验 appeared comparable。
关键数值与推荐
- 耐药/不耐受患者推荐II期剂量:博舒替尼400 mg/m2每日一次(最大600 mg/d)随餐。
- 初诊患者推荐II期剂量:博舒替尼300 mg/m2每日一次(最大500 mg/d)随餐。
- 推荐II期剂量标准:第一周期内0/6或1/10剂量限制性毒性且达到相应适应症成人目标AUC水平。
临床怎么用
- 耐药/不耐受的儿童慢性期慢性髓性白血病患者,博舒替尼推荐II期剂量为400 mg/m2每日一次(最大600 mg/d)随餐。
- 初诊的儿童慢性期慢性髓性白血病患者,博舒替尼推荐II期剂量为300 mg/m2每日一次(最大500 mg/d)随餐。
局限性
- 初诊患者仅入组II期,其推荐II期剂量基于耐药/不耐受患者数据选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bosutinib is approved for adults with chronic myeloid leukemia (CML): 400 mg once daily in newly diagnosed (ND); 500 mg once daily in resistant/intolerant (R/I) patients. Bosutinib has a different tolerability profile than other tyrosine kinase inhibitors (TKIs) and potentially less impact on growth (preclinical data). The primary objective of this first-in-child trial was to determine the recommended phase II dose (RP2D) for pediatric R/I and ND patients. PATIENTS AND METHODS: In the phase I part of this international, open-label trial (ClinicalTrials.gov identifier: NCT04258943), children age 1-18 years with R/I (per European LeukemiaNet 2013) Ph+ CML were enrolled using a 6 + 4 design, testing 300, 350, and 400 mg/m2 once daily with food. The RP2D was the dose resulting in 0/6 or 1/10 dose-limiting toxicities (DLTs) during the first cycle and achieving adult target AUC levels for the respective indication. As ND participants were only enrolled in phase II, the ND RP2D was selected based on data from R/I patients. RESULTS: Thirty patients were enrolled; 27 were evaluable for DLT: six at 300 mg/m2, 11 at 350 mg/m2 (one DLT), and 10 at 400 mg/m2 (one DLT). The mean AUCs at 300 mg/m2, 350 mg/m2, and 400 mg/m2 were 2.20 μg h/mL, 2.52 μg h/mL, and 2.66 μg h/mL, respectively. The most common adverse event was diarrhea (93%; ≥grade 3: 11%). Seven patients stopped because of intolerance and eight because of insufficient response. Complete cytogenetic and major molecular response to bosutinib appeared comparable with other published phase I/II trials with second-generation TKIs in children. CONCLUSION: Bosutinib was safe and effective. The pediatric RP2D was 400 mg/m2 once daily (max 600 mg/d) with food in R/I patients and 300 mg/m2 once daily (max 500 mg/d) with food in ND patients, which achieved targeted exposures as per adult experience.
引用
- Brivio E, Pennesi E, Willemse ME, et al. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2023. PMID: 38033284. doi:10.1200/JCO.23.00897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。